SCHEMBL3776873

SCHEMBL3776873

CC(C)(C)OC(=O)N1CCN(c2nc(-c3ccccc3F)cs2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
FAAH O00519 4/20 0.58
LMNA P02545 3/20 0.52
MAPT P10636 3/20 0.52
MAPK1 P28482 2/20 0.52
HTT P42858 1/20 0.52
USP30 Q70CQ3 1/20 0.48
SMARCA2 P51531 1/20 0.48
SMARCA4 P51532 1/20 0.48
PBRM1 Q86U86 1/20 0.48
AR P10275 2/20 0.47
SPR P35270 1/20 0.47
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ALDH1A1 P00352 1/20 0.45
CKS1B P61024 1/20 0.45
SKP1 P63208 1/20 0.45
SKP2 Q13309 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3775088 0.92 MAPT (0.50) SMN1; SMN2NPC1RAB9AFAAHLMNA
SCHEMBL3761098 0.88 FAAH (0.58) SMN1; SMN2NPC1RAB9AFAAHLMNA
SCHEMBL3774633 0.87 MAPT (0.52) SMN1; SMN2NPC1RAB9AFAAHLMNA
SCHEMBL12781817 0.87 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AFAAHLMNA
SCHEMBL12781801 0.86 REV1 (0.52) SMN1; SMN2NPC1RAB9AFAAHLMNA
SCHEMBL18702024 0.86 RAB9A (0.61) SMN1; SMN2NPC1RAB9AFAAHLMNA
SCHEMBL3765754 0.84 RAB9A (0.66) SMN1; SMN2NPC1RAB9AFAAHLMNA
SCHEMBL18711777 0.84 RAB9A (0.65) SMN1; SMN2NPC1RAB9AFAAHLMNA
SCHEMBL3774289 0.83 MAPT (0.50) SMN1; SMN2NPC1RAB9AFAAHLMNA
SCHEMBL3760999 0.83 RAB9A (0.66) SMN1; SMN2NPC1RAB9AFAAHLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
CN-101103007-A Amide compound TAKEDA PHARMACEUTICAL (JP) 2008-01-09 CN disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 SMN1; SMN2 2454/4885NPC1 1078/4885RAB9A 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.